Codex DNA, Inc. (DNAY) Bundle
Who's buying Codex DNA, Inc. (DNAY) and why the ownership mix matters: major filings show Northpond Ventures, LLC holds a commanding 9,840,000 shares (33.41%), Vanguard Group Inc. reportedly owns approximately 1,100,000 shares (9.8%), BlackRock, Inc. about 1,200,000 shares (10.5%), Fidelity Investments 900,000 shares (8.3%), Redmile Group 800,000 shares (7.2%) and Penn Capital Management 1,170,000 shares (3.98%); institutional investors collectively held 12.5 million shares, equal to 42.43% of shares outstanding as of December 31, 2022, while other reports list institutional ownership near 42.66%-set against a market capitalization of $38.379 million, a 60-month beta of 1.36 and a one-year return of -86.60%, these hard numbers frame the stakes for strategic influence, market credibility and future capital flows-read on to unpack who's steering DNAY and the implications of these concentrated positions.
Codex DNA, Inc. (DNAY): Who Invests in Codex DNA, Inc. (DNAY) and Why?
Institutional ownership in Codex DNA, Inc. (DNAY) is concentrated among a handful of strategic and diversified investors. The mix includes large asset managers, specialized biotech funds, and venture-focused investors - each bringing distinct time horizons, risk tolerances, and value-creation expectations.
- Vanguard Group Inc. - ~1,100,000 shares (9.8%): broad-market exposure with conviction in long-term synthetic biology growth and operational scale-up potential.
- BlackRock, Inc. - ~1,200,000 shares (10.5%): portfolio diversification into high-growth life-science themes and allocation to innovation-driven equities.
- Fidelity Investments, Inc. - ~900,000 shares (8.3%): long-term active stake emphasizing R&D pipeline commercialization and revenue expansion.
- Redmile Group, LLC - ~800,000 shares (7.2%): concentrated biotech specialist bet on disruptive platform and clinical/industrial inflection points.
- Northpond Ventures, LLC - 9,840,000 shares (33.41%): major strategic commitment consistent with venture/partner-style support and potential board/strategic influence.
- Penn Capital Management Company, LLC - ~1,170,000 shares (3.98%): diversified alternative/active strategy exposure to emerging biotech leaders.
| Investor | Approx. Shares | Reported Ownership | Investment Rationale |
|---|---|---|---|
| Vanguard Group Inc. | 1,100,000 | 9.8% | Index/ETF and passive plus selective active positions for long-term sector growth |
| BlackRock, Inc. | 1,200,000 | 10.5% | Diversification into synthetic biology and allocation to thematic growth strategies |
| Fidelity Investments, Inc. | 900,000 | 8.3% | Active, long-term investment betting on commercialization and revenue trajectory |
| Redmile Group, LLC | 800,000 | 7.2% | Specialist biotech exposure seeking clinical/technical inflection-driven upside |
| Northpond Ventures, LLC | 9,840,000 | 33.41% | Venture/strategic backing with significant ownership to influence direction |
| Penn Capital Management Co., LLC | 1,170,000 | 3.98% | Active diversified strategy allocating to promising biotech equities |
Key themes driving these holdings include platform scalability, addressable market in synthetic biology and gene synthesis, nearer-term commercialization milestones, and strategic alignment with partners and research customers. For additional context about the company's strategic orientation and values, see: Mission Statement, Vision, & Core Values (2026) of Codex DNA, Inc.
Institutional Ownership and Major Shareholders of Codex DNA, Inc. (DNAY)
As of December 31, 2022, institutional investors collectively held 12.5 million shares of Codex DNA, Inc. (DNAY), representing 42.43% of the company's total shares outstanding. This ownership profile highlights a concentrated institutional base with several large, strategic holders.- Total institutional holdings (12/31/2022): 12,500,000 shares (42.43% of shares outstanding)
- Largest institutional investor: Northpond Ventures, LLC - 33.41% ownership
- Other notable institutional holders:
- Fidelity Investments, Inc. - 8.30%
- Redmile Group, LLC - 7.20%
- Penn Capital Management Company, LLC - 3.98%
- Vanguard Group Inc. - 1.39%
- BlackRock, Inc. - 0.09%
| Institution | Shares Held (approx.) | Ownership % | Investor Type / Note |
|---|---|---|---|
| Northpond Ventures, LLC | ~9,857,500 | 33.41% | Lead institutional sponsor; strategic biotech investor |
| Fidelity Investments, Inc. | ~2,447,500 | 8.30% | Long-term mutual fund/asset manager |
| Redmile Group, LLC | ~2,120,000 | 7.20% | Biotech-focused hedge/asset manager |
| Penn Capital Management Co., LLC | ~1,171,000 | 3.98% | Diversified investment manager |
| Vanguard Group Inc. | ~408,500 | 1.39% | Index and active asset manager |
| BlackRock, Inc. | ~26,500 | 0.09% | Global asset manager |
Codex DNA, Inc. (DNAY) - Key Investors and Their Impact on Codex DNA, Inc. (DNAY)
Codex DNA, Inc. (DNAY) exhibits a concentrated ownership profile with several institutional holders whose stakes and investment horizons materially shape governance, capital access, and market perception. The largest holders outlined below combine strategic influence, long-term support, and thematic biotech conviction.- Significant influence and control: Northpond Ventures, LLC holds a 33.41% stake, positioning it as the single largest influence on board composition, strategic partnerships, capital raises, and potential M&A direction.
- Long-term institutional support: Fidelity Investments, Inc. (8.3%) and Redmile Group, LLC (7.2%) provide stability and sector expertise that can temper share volatility during research milestones or financing events.
- Diversified institutional participation: Penn Capital Management Company, LLC (3.98%), Vanguard Group Inc. (1.39%), and BlackRock, Inc. (0.09%) signal broad institutional interest that can improve liquidity and market credibility.
| Investor | Reported Ownership (%) | Potential Strategic Impact |
|---|---|---|
| Northpond Ventures, LLC | 33.41% | Major governance influence; potential to steer R&D prioritization, board seats, and capital strategy. |
| Fidelity Investments, Inc. | 8.30% | Long-term institutional holder; may provide steadying influence and support for multi-year growth plans. |
| Redmile Group, LLC | 7.20% | Thematic biotech investor; likely to back innovation initiatives and industry collaborations. |
| Penn Capital Management Company, LLC | 3.98% | Diversified asset manager; enhances credibility and can participate in follow-on financings. |
| Vanguard Group Inc. | 1.39% | Index/ETF and active strategies exposure; reflects confidence in growth potential and aids passive demand. |
| BlackRock, Inc. | 0.09% | Strategic signaling to broader institutional investors; minor stake but notable name recognition. |
- Governance dynamics: With a >33% stake, Northpond can effectively influence board decisions-expect alignment between R&D milestones and capital allocation reflecting its portfolio priorities.
- Volatility and liquidity: Combined institutional ownership (notably Fidelity, Redmile, and Penn) tends to reduce short-term volatility while supporting liquidity through programmatic trading and fund flows.
- Capital markets implications: Presence of large asset managers (Vanguard, BlackRock) may improve analyst coverage and index inclusion likelihood, which can lift passive inflows.
- Strategic partnerships and commercialization: Redmile's biotech focus increases the chance of collaboration introductions and co-development opportunities.
Codex DNA, Inc. (DNAY) Market Impact and Investor Sentiment
Codex DNA, Inc. (DNAY) occupies a niche at the intersection of synthetic biology and next‑generation DNA synthesis. Recent market behavior shows both risk and institutional endorsement: market capitalization is $38.379 million, a 60‑month beta of 1.36 (moderate volatility relative to the market), and a 1‑year return of -86.60%, reflecting steep short‑term share price declines amid broader sector and company‑specific pressures.- Institutional ownership: 42.66% - a substantial stake that signals confidence from large, professional investors.
- Notable institutional holders include Vanguard and BlackRock, which can lend credibility and improve liquidity profiles.
- Sector positioning: synthetic biology / DNA synthesis - an area with large addressable market potential but high R&D and commercialization risk.
| Metric | Value |
|---|---|
| Market Capitalization | $38.379 million |
| 60‑Month Beta | 1.36 |
| 1‑Year Total Return | -86.60% |
| Institutional Ownership | 42.66% |
| Major Institutional Investors | Vanguard, BlackRock (among others) |
| Primary Market Focus | Synthetic biology / DNA synthesis technologies |
| Strategic Drivers | Collaborations, partnerships, product commercialization |
- Buy-side rationale: strategic exposure to synthetic biology growth, potential for high future margins if platforms scale, and institutional endorsement.
- Sell/hold rationale: severe near‑term stock decline (-86.60% YTD), execution and cash‑burn risk, and high uncertainty on timing of revenue scaling.
- Sentiment drivers to monitor: partnership announcements, proof‑of‑concept or commercialization milestones, quarterly cash runway updates, and any shifts in institutional holdings.
Codex DNA, Inc. (DNAY) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.